Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Medical cannabis for neuropathic pain and spasticity in multiple sclerosis or spinal cord injury
2018-002315-98Phase 2Completed
- Sponsor
- Aarhus University Hospital
- Start
- Jul 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of cannabidiol and dronabinol in multiple sclerosis (MS) and spinal cord injury (SCI) (4 arms), sponsored by Aarhus University Hospital. Primary endpoint: Mean pain intensity during the last week of active treatment compared with baseline. Started Jul 2018; status: completed.
02
Drugs
cannabidioldronabinol
03
Conditions
multiple sclerosis (MS)spinal cord injury (SCI)
Beyond the preview
Go deeper on 2018-002315-98.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002315-98.